Intended for healthcare professionals

CCBYNC Open access

Rapid response to:

Research

Cardiovascular outcomes associated with canagliflozin versus other non-gliflozin antidiabetic drugs: population based cohort study

BMJ 2018; 360 doi: https://doi.org/10.1136/bmj.k119 (Published 06 February 2018) Cite this as: BMJ 2018;360:k119

Rapid Response:

Re: Cardiovascular outcomes associated with canagliflozin versus other non-gliflozin antidiabetic drugs: population based cohort study

Dear Prof. Elisabetta Patorno et al:

Taking into account that:

First, Canaglifozin is also a glycosuric diuretic drug, so increasing blood viscosity (1).

Second, Canaglifozin has been associated with increased lower limb amputations in previous randomised clinical trial (2).

In this large retrospective cohort, would it possible to inform us the incidence of amputations with the use of Canaglifozin compared to the other anti-diabetic drugs?

REFERENCES:

1. Poredos P, Zizek B. Plasma viscosity increase with progression of peripheral arterial atherosclerotic disease. Angiology 1996;47:253-259.
2. Bruce Neal, M.B., Ch.B., Ph.D., Vlado Perkovic, M.B., B.S., Ph.D., Kenneth W. Mahaffey, M.D., Dick de Zeeuw, M.D., Ph.D., Greg Fulcher, M.D., Ngozi Erondu, M.D., Ph.D., Wayne Shaw, D.S.L., Gordon Law, Ph.D., Mehul Desai, M.D., and David R. Matthews, .Phil., B.M., B.Ch. for the CANVAS Program Collaborative Group. N Engl J Med 2017; 377:644-657
DOI: 10.1056/NEJMoa1611925

Competing interests: No competing interests

07 February 2018
Jose Mario Franco de Oliveira
Associate Professor of Medicine.
Department of Medicine. Universidade Federal Fluminense.
Rua Senador Vergueiro # 2 Apt. 202. Rio de Janeiro, RJ, Brazil.